The Journal of Practical Medicine ›› 2023, Vol. 39 ›› Issue (12): 1571-1576.doi: 10.3969/j.issn.1006⁃5725.2023.12.019

• Reviews • Previous Articles     Next Articles

Research progress of ferroptosis in gemcitabine resistance in pancreatic cancer 

LI Xiang*,TIAN Guofeng, XIAO Wanru,HAO Liang.    

  1. Department of Chemistry,School of Forensic Medicine,China Medical University, Shenyang 110122,China;*Liaoning Province Key Laboratory of Forensic Bio ⁃ evidence Sciences,Shenyang 110122,China;*China Medical University Center of Forensic Investigation,Shenyang 110122,China;*The First Department of Clinic,Class of 2019,China Medical University,Shenyang 110000,China 
  • Online:2023-06-25 Published:2023-06-25
  • Contact: HAO Liang E⁃mail:haoliangdut@163.com

Abstract:

Pancreatic cancer(PC),as one of the digestive tract tumors with the lowest survival rate and the worst prognosis,is known as the“king of cancers”. Most patients have lost the opportunity for radical resection at diagnosis and have developed resistance to gemcitabine(GEM),the first ⁃line chemotherapy agent,further reducing the effectiveness of treatment. In recent years,ferroptosis a new type of iron⁃dependent cell programmed death,and its regulatory mechanism has been widely studied and applied in the treatment of pancreatic cancer. Ex⁃ perimental studies have shown that inducing ferroptosis in pancreatic cancer cells can effectively reduce their resis⁃ tance to chemotherapy drugs. In this paper,the role of ferroptosis in gemcitabine resistance of pancreatic cancer were reviewed,aiming to provide new ideas and directions for the study of the treatment of pancreatic cancer based on ferroptosis. 

Key words: ferroptosis, pancreatic cancer, gemcitabine resistance